FR2515960A1 - Nanocapsules ou nanoparticules biodegradables contenant une substance biologiquement active, leur preparation et leur application - Google Patents
Nanocapsules ou nanoparticules biodegradables contenant une substance biologiquement active, leur preparation et leur application Download PDFInfo
- Publication number
- FR2515960A1 FR2515960A1 FR8120801A FR8120801A FR2515960A1 FR 2515960 A1 FR2515960 A1 FR 2515960A1 FR 8120801 A FR8120801 A FR 8120801A FR 8120801 A FR8120801 A FR 8120801A FR 2515960 A1 FR2515960 A1 FR 2515960A1
- Authority
- FR
- France
- Prior art keywords
- nanocapsules
- active substance
- biologically active
- sep
- nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001651 Cyanoacrylate Polymers 0.000 title claims abstract description 11
- -1 alkyl cyanoacrylate Chemical compound 0.000 title claims description 11
- 239000002775 capsule Substances 0.000 title 1
- 239000002088 nanocapsule Substances 0.000 claims abstract description 80
- 239000002105 nanoparticle Substances 0.000 claims abstract description 31
- 229940088623 biologically active substance Drugs 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 239000013543 active substance Substances 0.000 claims description 15
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 10
- 238000006116 polymerization reaction Methods 0.000 claims description 8
- 239000008346 aqueous phase Substances 0.000 claims description 6
- 239000000186 progesterone Substances 0.000 claims description 6
- 229960003387 progesterone Drugs 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 239000011630 iodine Substances 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 claims description 3
- 239000002736 nonionic surfactant Substances 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 239000013566 allergen Substances 0.000 claims description 2
- 230000002927 anti-mitotic effect Effects 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 230000003054 hormonal effect Effects 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims 2
- 230000000118 anti-neoplastic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 3
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 abstract 2
- 239000003921 oil Substances 0.000 description 20
- 235000019198 oils Nutrition 0.000 description 19
- 239000000178 monomer Substances 0.000 description 14
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 13
- 239000002245 particle Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- 229920001993 poloxamer 188 Polymers 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 102100021906 Cyclin-O Human genes 0.000 description 8
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 8
- 238000005538 encapsulation Methods 0.000 description 7
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 6
- QRWOVIRDHQJFDB-UHFFFAOYSA-N isobutyl cyanoacrylate Chemical compound CC(C)COC(=O)C(=C)C#N QRWOVIRDHQJFDB-UHFFFAOYSA-N 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 229960002247 lomustine Drugs 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical class C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 3
- 238000003760 magnetic stirring Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000012137 double-staining Methods 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 235000021388 linseed oil Nutrition 0.000 description 2
- 239000000944 linseed oil Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 2
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- KOACPIVVJXJTHO-UHFFFAOYSA-N 2-(cyanomethylidene)-4-methylpentanoic acid Chemical compound CC(C)CC(C(O)=O)=CC#N KOACPIVVJXJTHO-UHFFFAOYSA-N 0.000 description 1
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- MVTQIFVKRXBCHS-SMMNFGSLSA-N N-[(3S,6S,12R,15S,16R,19S,22S)-3-benzyl-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide (10R,11R,12E,17E,19E,21S)-21-hydroxy-11,19-dimethyl-10-propan-2-yl-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.03,7]octacosa-1(27),6,12,17,19,25(28)-hexaene-2,8,14,23-tetrone Chemical compound CC(C)[C@H]1OC(=O)C2=CCCN2C(=O)c2coc(CC(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@H]1C)n2.CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@@H]2CC(=O)CCN2C(=O)[C@H](Cc2ccccc2)N(C)C(=O)[C@@H]2CCCN2C1=O)c1ccccc1 MVTQIFVKRXBCHS-SMMNFGSLSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 108010080702 Virginiamycin Proteins 0.000 description 1
- 239000004188 Virginiamycin Substances 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical group [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 235000019720 niaouli oil Nutrition 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 229940075469 tissue adhesives Drugs 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960003842 virginiamycin Drugs 0.000 description 1
- 235000019373 virginiamycin Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8120801A FR2515960A1 (fr) | 1981-11-06 | 1981-11-06 | Nanocapsules ou nanoparticules biodegradables contenant une substance biologiquement active, leur preparation et leur application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8120801A FR2515960A1 (fr) | 1981-11-06 | 1981-11-06 | Nanocapsules ou nanoparticules biodegradables contenant une substance biologiquement active, leur preparation et leur application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2515960A1 true FR2515960A1 (fr) | 1983-05-13 |
| FR2515960B1 FR2515960B1 (OSRAM) | 1984-02-10 |
Family
ID=9263749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8120801A Granted FR2515960A1 (fr) | 1981-11-06 | 1981-11-06 | Nanocapsules ou nanoparticules biodegradables contenant une substance biologiquement active, leur preparation et leur application |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2515960A1 (OSRAM) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4579730A (en) * | 1983-05-23 | 1986-04-01 | Hadassah Medical Organization | Pharmaceutical compositions containing insulin |
| EP0167825A3 (en) * | 1984-06-08 | 1987-01-21 | Dr. Rentschler Arzneimittel Gmbh & Co. | Lipid nano pellets as drug carriers for oral administration |
| EP0447318A1 (fr) * | 1990-03-16 | 1991-09-18 | L'oreal | Composition pour le traitement cosmétique et/ou pharmaceutique des couches supérieures de l'épiderme par application topique sur la peau et procédé de préparation correspondant |
| DE4128910A1 (de) * | 1991-08-08 | 1993-02-11 | Cusi Lab | Verfahren zur kontinuierlichen herstellung feinverteilter kolloidsysteme in form von nanokapseln oder nanopartikeln |
| EP0608207A1 (fr) * | 1993-01-18 | 1994-07-27 | U C B, S.A. | Compositions pharmaceutiques contenant des nanocapsules |
| EP0621073A1 (en) * | 1993-04-20 | 1994-10-26 | Laboratorios Cusi, S.A. | Method to increase the stability of nanocapsules during storage thereof |
| WO2002072535A1 (de) * | 2001-03-09 | 2002-09-19 | Henkel Kommanditgesellschaft Auf Aktien | Modifizierte cyanacrylatester, daraus hergestellte nano- oder mikrokapseln und deren verwendung in wasch- oder reinigungsmitteln |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4173868A (en) * | 1968-08-06 | 1970-02-12 | The Champion Paper Company Ltd | Microencapsulation process and products |
| GB1354693A (en) * | 1970-08-13 | 1974-06-05 | Magnesium Elektron Ltd | Encapsulation of fluids and solds |
| FR2208716A1 (OSRAM) * | 1972-12-04 | 1974-06-28 | Speiser Peter | |
| BE869107A (fr) * | 1978-07-19 | 1979-01-19 | Couvreur Patrick | Particules submicroscopiques biodegradables contenant une substance biologiquement active, leur preparation et leur application |
| FR2437831A1 (fr) * | 1978-10-05 | 1980-04-30 | Daeniker Felix | Agent de contraste pour l'examen radiologique du foie et procede pour sa preparation |
-
1981
- 1981-11-06 FR FR8120801A patent/FR2515960A1/fr active Granted
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4173868A (en) * | 1968-08-06 | 1970-02-12 | The Champion Paper Company Ltd | Microencapsulation process and products |
| GB1354693A (en) * | 1970-08-13 | 1974-06-05 | Magnesium Elektron Ltd | Encapsulation of fluids and solds |
| FR2208716A1 (OSRAM) * | 1972-12-04 | 1974-06-28 | Speiser Peter | |
| BE869107A (fr) * | 1978-07-19 | 1979-01-19 | Couvreur Patrick | Particules submicroscopiques biodegradables contenant une substance biologiquement active, leur preparation et leur application |
| FR2437831A1 (fr) * | 1978-10-05 | 1980-04-30 | Daeniker Felix | Agent de contraste pour l'examen radiologique du foie et procede pour sa preparation |
Non-Patent Citations (1)
| Title |
|---|
| CA1982 * |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4579730A (en) * | 1983-05-23 | 1986-04-01 | Hadassah Medical Organization | Pharmaceutical compositions containing insulin |
| EP0167825A3 (en) * | 1984-06-08 | 1987-01-21 | Dr. Rentschler Arzneimittel Gmbh & Co. | Lipid nano pellets as drug carriers for oral administration |
| JPH05148129A (ja) * | 1990-03-16 | 1993-06-15 | L'oreal Sa | 皮膚への局所適用による表皮上層の化粧的および（または）薬学的処置のための組成物およびその製造方法 |
| FR2659554A1 (fr) * | 1990-03-16 | 1991-09-20 | Oreal | Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant. |
| EP0447318A1 (fr) * | 1990-03-16 | 1991-09-18 | L'oreal | Composition pour le traitement cosmétique et/ou pharmaceutique des couches supérieures de l'épiderme par application topique sur la peau et procédé de préparation correspondant |
| US6203802B1 (en) | 1990-03-16 | 2001-03-20 | L'oreal | Composition for the cosmetic and/or pharmaceutical treatment of the upper layers of the epidermis by topical application to the skin, and corresponding preparation process |
| DE4128910A1 (de) * | 1991-08-08 | 1993-02-11 | Cusi Lab | Verfahren zur kontinuierlichen herstellung feinverteilter kolloidsysteme in form von nanokapseln oder nanopartikeln |
| EP0529711A1 (en) * | 1991-08-08 | 1993-03-03 | Laboratorios Cusi, S.A. | Process of continuous preparation of disperse colloidal systems in the form of nanocapsules or nanoparticles |
| US5705196A (en) * | 1991-08-08 | 1998-01-06 | Laboratorios Cusi, S.A. | Process of continuous preparation of disperse colloidal systems in the form of nanocapsules or nanoparticles |
| EP0608207A1 (fr) * | 1993-01-18 | 1994-07-27 | U C B, S.A. | Compositions pharmaceutiques contenant des nanocapsules |
| US5500224A (en) * | 1993-01-18 | 1996-03-19 | U C B S.A. | Pharmaceutical compositions containing nanocapsules |
| AU670840B2 (en) * | 1993-01-18 | 1996-08-01 | Ucb | Pharmaceutical compositions containing nanocapsules |
| EP0621073A1 (en) * | 1993-04-20 | 1994-10-26 | Laboratorios Cusi, S.A. | Method to increase the stability of nanocapsules during storage thereof |
| WO2002072535A1 (de) * | 2001-03-09 | 2002-09-19 | Henkel Kommanditgesellschaft Auf Aktien | Modifizierte cyanacrylatester, daraus hergestellte nano- oder mikrokapseln und deren verwendung in wasch- oder reinigungsmitteln |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2515960B1 (OSRAM) | 1984-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0007895B1 (fr) | Nanoparticules biodégradables, compositions pharmaceutiques les contenant et procédé pour leur préparation | |
| EP0646003B1 (fr) | Preparation et utilisation de nouveaux systemes colloidaux dispersibles a base de cyclodextrine, sous forme de nanospheres | |
| EP0275796B2 (fr) | Procédé de préparation de systèmes colloidaux dispersibles d'une substance, sous forme du nanoparticules | |
| EP0274961B1 (fr) | Procédé de préparation de systèmes colloidaux dispersibles d'une substance, sous forme de nanocapsules | |
| EP0064967B1 (fr) | Procédé de préparation de particules submicroscopiques, particules ainsi obtenues et compositions pharmaceutiques les contenant | |
| EP0608207B1 (fr) | Compositions pharmaceutiques contenant des nanocapsules | |
| BE1006143A3 (fr) | Sels de peptides avec des polyesters carboxytermines. | |
| WO1997004749A1 (fr) | Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees | |
| EP2381931B1 (fr) | Composition comprenant un actif de faible solubilité aqueuse | |
| EP0804173B1 (fr) | Microspheres biodegradables a liberation controlee et leur procede de preparation | |
| FR2755136A1 (fr) | Procede de preparation de nanoparticules de methylidene malonate, nanoparticules contenant eventuellement une ou plusieurs molecules biologiquement actives et compositions pharmaceutiques les contenant | |
| EP1003488A1 (fr) | Procede de preparation de nanocapsules de type vesiculaire | |
| KR101542138B1 (ko) | 폴리도파민계 나노입자, 불수용성 약물이 표면에 코팅된 폴리도파민계 나노입자 및 이들의 제조방법 | |
| FR2515960A1 (fr) | Nanocapsules ou nanoparticules biodegradables contenant une substance biologiquement active, leur preparation et leur application | |
| FR2806005A1 (fr) | Procede de preparation de particules colloidales sous forme de nanocapsules | |
| FR2769854A1 (fr) | Nouveau procede d'obtention de microspheres et les produits ainsi realises | |
| EP0646002B1 (fr) | Preparation et application de nouveaux systemes colloidaux nanovesiculaires dispersibles a base de cyclodextrine, sous forme de nanocapsules | |
| FR2816949A1 (fr) | Copolymere a structure sequencee compose d'un segment saccharidique lie a au moins un segment hydrophobe bioerodable, et particules correspondantes | |
| EP1232188B1 (fr) | Cyclodextrines substituees par des groupements fluoroalkyles, leur preparation et leur utilisation | |
| CN118766855B (zh) | 一种适用于关节腔注射的具有核-壳结构的双效药物缓释微球系统的制备方法 | |
| WO2023242280A1 (fr) | Microcapsule chargee d'une substance active et comprenant une ouverture micrometrique | |
| WO2025191383A1 (fr) | Assemblage moléculaire pour l'encapsulation de molécules hydrophobes, ledit assemblage ayant les molécules hydrophobes encapsulées, procédés de fabrication correspondants et utilisations | |
| Arora et al. | Formulation and Characterization of Nifedipine loaded Nanostructured Lipid Carriers coated with Fenugreek Seed Polysaccharide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CA | Change of address | ||
| ST | Notification of lapse | ||
| RN | Application for restoration | ||
| FC | Favourable decision of inpi director general on an application for restauration. |